LEUKEMIAS

FDA fast-tracks QTX-2101, an oral arsenic trioxide therapy, enhancing treatment accessibility for acute promyelocytic leukemia patients.

FDA grants orphan drug designation to CTD402, a promising CAR T therapy for relapsed T-cell leukemia and lymphoma, enhancing treatment accessibility.

The FDA approves a larger vial of nelarabine injection, enhancing treatment flexibility for T-cell leukemia in adults and children.

A long-term study reveals that blinatumomab significantly enhances survival rates in infants with KMT2A-rearranged ALL, offering hope for improved treatment outcomes.

Combination therapies using PD-1/PD-L1 inhibitors enhance survival rates in relapsed/refractory acute lymphoblastic leukemia without added toxicity.

A new study reveals that combining ianalumab with ibrutinib offers promising results for chronic lymphocytic leukemia, enabling some patients to stop therapy.

The FDA designates ICT01 as a breakthrough therapy for unfit AML patients, showcasing promising efficacy in early clinical trials.

New research reveals that ropeginterferon alfa-2b offers no significant benefits over observation after TKI cessation in chronic myeloid leukemia patients.

New research reveals that combining midostaurin with standard chemotherapy significantly improves survival rates and reduces minimal residual disease in AML patients.

A phase 3 study is evaluating olverembatinib with chemotherapy for treating Philadelphia chromosome–positive acute lymphoblastic leukemia, showing promising efficacy and safety.

A phase 1b/2 trial reveals MK-1045 shows manageable safety and promising efficacy in treating relapsed/refractory B-cell acute lymphoblastic leukemia.

Families of children with acute lymphoblastic leukemia face significant financial challenges during treatment, with many experiencing material hardship and income loss.

The KOMET-007 trial reveals promising safety and efficacy of ziftomenib combined with venetoclax and azacitidine for relapsed/refractory AML patients.

A recent study reveals that Black patients with acute myeloid leukemia face significantly poorer survival rates compared to White patients, highlighting racial disparities in treatment outcomes.

A new combination therapy shows promising results in achieving durable remission for patients with NPM1-mutated acute myeloid leukemia.

NXC-201 CAR T-cell therapy shows promising results in treating relapsed AL amyloidosis, achieving deep responses and rapid normalization of disease markers.

The SAVE regimen demonstrates promising efficacy in newly diagnosed AML, achieving high response rates but raises concerns about myelosuppression.

A promising trial reveals high response rates and survival outcomes for decitabine/cedazuridine and venetoclax in high-risk hematologic malignancies.

New research highlights measurable residual disease (MRD) as a key predictor of survival in acute myeloid leukemia, potentially transforming treatment strategies.

Azacitidine plus venetoclax significantly enhances event-free survival and quality of life in acute myeloid leukemia patients compared with traditional chemotherapy.

During a live event, Praneeth Baratam, MBBS, discussed long-term data from a trial comparing luspatercept with epoetin alfa in low-risk myelodysplastic syndromes.

A clinical trial of the menin inhibitor DS-1594b in patients with relapsed leukemia has been terminated due to inefficacy, revealing safety challenges and insights for future therapies.

CLN-049 gains FDA fast track designation, offering hope for patients with relapsed/refractory AML through innovative immunotherapy solutions.